CG Oncology (NASDAQ:CGON) Trading Up 7.9%

CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) traded up 7.9% during mid-day trading on Tuesday . The company traded as high as $36.67 and last traded at $36.19. 150,264 shares were traded during trading, a decline of 76% from the average session volume of 621,993 shares. The stock had previously closed at $33.54.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Morgan Stanley assumed coverage on shares of CG Oncology in a report on Tuesday, February 20th. They set an "overweight" rating and a $55.00 price target for the company. The Goldman Sachs Group assumed coverage on shares of CG Oncology in a report on Tuesday, February 20th. They set a "neutral" rating and a $42.00 price target for the company. Cantor Fitzgerald assumed coverage on shares of CG Oncology in a report on Tuesday, February 20th. They set an "overweight" rating and a $75.00 price target for the company. Finally, HC Wainwright restated a "buy" rating and set a $75.00 price target on shares of CG Oncology in a report on Thursday, April 4th.

CG Oncology Stock Performance

The business's fifty day moving average is $40.85.

Insiders Place Their Bets

In other CG Oncology news, Director Hong Fang Song purchased 263,157 shares of the company's stock in a transaction on Monday, January 29th. The stock was acquired at an average price of $19.00 per share, for a total transaction of $4,999,983.00. Following the completion of the purchase, the director now directly owns 613,928 shares in the company, valued at approximately $11,664,632. The purchase was disclosed in a filing with the SEC, which is available through this link. In other news, CFO Corleen M. Roche acquired 2,000 shares of the firm's stock in a transaction dated Monday, January 29th. The stock was acquired at an average cost of $19.00 per share, with a total value of $38,000.00. Following the transaction, the chief financial officer now owns 2,000 shares in the company, valued at $38,000. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Hong Fang Song acquired 263,157 shares of the firm's stock in a transaction dated Monday, January 29th. The shares were purchased at an average cost of $19.00 per share, with a total value of $4,999,983.00. Following the completion of the transaction, the director now owns 613,928 shares in the company, valued at approximately $11,664,632. The disclosure for this purchase can be found here. Insiders acquired a total of 666,472 shares of company stock worth $12,662,968 over the last 90 days.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.